Loading stock data…
$1.72-0.04 (-2.27%)
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Tenax Therapeutics, Inc. in the Healthcare sector is trading at $1.72 with a market capitalization of $70M. Wall Street consensus targets $9.62 (8 analysts), implying a +459.6% move over the next 12 months. The stock is currently near its 52-week low of $1.31, remaining 83.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.78M↓ | -$16.57M↓ | -$16.45M↑ | -$16.81M↓ | -$11.79M |
| Net Income | -$17.80M↓ | -$15.72M↓ | -$15.54M↑ | -$15.80M↓ | -$10.85M |
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatme...